Clinical Trials
25 trialsNCT02106572 2026-05-22
TIM
Abnoba Gmbh
Phase 3 Terminated
NCT05243550 2026-05-11
ENVISION
UroGen Pharma Ltd.
Phase 3 Active not recruiting
NCT06211764 2026-05-08
SunRISe-5
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06919965 2026-05-08
MoonRISe-3
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06704191 2026-03-30
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
Phase 1/2 Recruiting
NCT04172675 2026-02-24
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
Phase 2 Completed
NCT07424287 2026-02-20
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Not yet recruiting
NCT06331299 2026-01-15
UTOPIA
UroGen Pharma Ltd.
Phase 3 Active not recruiting
NCT06781879 2025-10-03
COBRA-NMIBC
Aarhus University Hospital
Phase 4 Recruiting
NCT07189793 2025-09-24
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT06696794 2025-02-19
Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients
Tongji Hospital
Phase 3 Recruiting
NCT05136898 2024-09-19
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 3 Completed
NCT04688931 2024-06-06
ATLAS
UroGen Pharma Ltd.
Phase 3 Terminated
NCT06227065 2024-01-26
POLO
University of Bern
Phase 2 Not yet recruiting
NCT02695771 2023-04-21
BIC
Corewell Health West
Phase 3 Completed
NCT05547516 2022-09-21
BL-PDT-RCT
First Affiliated Hospital Xi'an Jiaotong University
Phase NA Unknown
NCT03558503 2022-09-16
OPTIMA II
UroGen Pharma Ltd.
Phase 2 Completed
NCT02316171 2022-07-27
CANON
Viralytics
Phase 1 Completed
NCT00318643 2021-10-29
Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer
Halozyme Therapeutics
Phase 1/2 Completed
NCT02982395 2019-08-30
Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC
Samyang Biopharmaceuticals Corporation
Phase 3 Terminated
NCT02307487 2017-06-16
Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients
UroGen Pharma Ltd.
Phase 2 Completed
NCT00734994 2015-06-29
Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer
Duke University
Phase EARLY_PHASE1 Completed
NCT01920269 2013-08-09
EMDA/MMC
University of Rome Tor Vergata
Phase 2/3 Completed
NCT01149174 2011-10-04
EMDA/PRE-TUR
University of Rome Tor Vergata
Phase 3 Completed
NCT00192049 2007-05-17
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
Eli Lilly and Company
Phase 2 Completed